<CodeList xmlns="http://www.cdisc.org/ns/odm/v1.3" xmlns:nciodm="http://ncicb.nci.nih.gov/xml/odm/EVS/CDISC" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" OID="CL.C119016.CVFARS" Name="Cardiovascular Findings About Results" DataType="text" nciodm:ExtCodeID="C119016" nciodm:CodeListExtensible="No">
                <Description>
                    <TranslatedText xml:lang="en">Terminology responses used for the cardiovascular findings about test codes and names codelist within CDISC.</TranslatedText>
                </Description>
                <EnumeratedItem CodedValue="ANGIOGRAPHY" nciodm:ExtCodeID="C20080">
                    <nciodm:CDISCDefinition>A method used to create an image of blood vessels.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Angiography</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="AUGMENTATION OF ORAL DIURETIC THERAPY" nciodm:ExtCodeID="C119199">
                    <nciodm:CDISCDefinition>Initiation or intensification of orally administered medication(s) that promote diuresis to treat heart failure.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Oral Diuretic Therapy Augmentation for Heart Failure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="AUTOPSY" nciodm:ExtCodeID="C25153">
                    <nciodm:CDISCDefinition>A postmortem examination of the body.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Autopsy</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="CLINICALLY SIGNIFICANT OR RAPID WEIGHT GAIN" nciodm:ExtCodeID="C119200">
                    <nciodm:CDISCDefinition>Weight gain thought to be related to fluid retention.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Weight Gain Due to Fluid Retention</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="CORONARY LESION ON ANGIOGRAPHY" nciodm:ExtCodeID="C119201">
                    <nciodm:CDISCDefinition>Angiographic evidence of new or worse greater than or equal to 70 percent lesion and/or thrombus in an epicardial coronary artery believed to be responsible for the myocardial ischemic symptoms/signs. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Coronary Lesion by Angiographic Finding</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="CORONARY REVASCULARIZATION" nciodm:ExtCodeID="C119202">
                    <nciodm:CDISCDefinition>Need for coronary revascularization procedure (PCI or CABG) for the presumed culprit lesion(s). This criterion would be fulfilled if revascularization was undertaken during the unscheduled hospitalization, or subsequent to transfer to another institution without interceding home discharge. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Coronary Revascularization Procedure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="DECREASED EXERCISE TOLERANCE" nciodm:ExtCodeID="C119203">
                    <nciodm:CDISCDefinition>Reduced ability to withstand or participate in activities that induce physical or mental exertion.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Decreased Exercise Tolerance</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="DYSPNEA" nciodm:ExtCodeID="C2998">
                    <nciodm:CDISCDefinition>Includes dyspnea on exertion, dyspnea at rest, orthopnea, and paroxysmal nocturnal dyspnea.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Dyspnea</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="FATIGUE" nciodm:ExtCodeID="C3036">
                    <nciodm:CDISCDefinition>Unusual tiredness and inability to perform usual activities.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Fatigue</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="HEART FAILURE HOSPITALIZATION" nciodm:ExtCodeID="C119204">
                    <nciodm:CDISCDefinition>An event where the patient is admitted to the hospital with a primary diagnosis of heart failure (HF), where the length of stay is at least 24 hours (or extends over a calendar date), where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Hospitalization Due to Heart Failure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="HEMORRHAGIC STROKE" nciodm:ExtCodeID="C95803">
                    <nciodm:CDISCDefinition>An acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Hemorrhagic Cerebrovascular Accident</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INCREASE IN HEART FAILURE BIOMARKER" nciodm:ExtCodeID="C119205">
                    <nciodm:CDISCDefinition>Biomarker increase (B-type natriuretic peptide (BNP)/ N-terminal pro-BNP (NT-proBNP)) consistent with decompensation of heart failure (such as BNP greater than 500 pg/mL or NT-proBNP greater than 2,000 pg/mL). In patients with chronically elevated natriuretic peptides, a significant increase above baseline is required. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Increase in B-type Natriuretic Peptide or N-terminal pro-B-type Natriuretic Peptide</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INCREASED JUGULAR VENOUS PRESSURE OR HEPATOJUGULAR REFLUX" nciodm:ExtCodeID="C119206">
                    <nciodm:CDISCDefinition>Increase in the estimated height of the mean jugular venous waveform above the right atrium in cm.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Increase in Jugular Venous Pressure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INCREASING ABDOMINAL DISTENTION OR ASCITES" nciodm:ExtCodeID="C2885">
                    <nciodm:CDISCDefinition>Intra-abdominal fluid accumulation as determined by physical examination (in the absence of primary hepatic disease).</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Ascites</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INDUCIBLE MYOCARDIAL ISCHEMIA" nciodm:ExtCodeID="C119207">
                    <nciodm:CDISCDefinition>Definite evidence of inducible myocardial ischemia believed to be responsible for the myocardial ischemic symptoms/signs, demonstrated by any of the following: a) an early positive exercise stress test, defined as ST elevation of greater than or equal to 2 mm ST depression prior to 5 mets, b) stress echocardiography (reversible wall motion abnormality), c) myocardial scintigraphy (reversible perfusion defect), d) MRI (myocardial perfusion deficit under pharmacologic stress). (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Inducible Myocardial Ischemia</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INTRAVENOUS DIURETIC, INOTROPE, OR VASODILATOR THERAPY" nciodm:ExtCodeID="C119208">
                    <nciodm:CDISCDefinition>Initiation or intensification of medication(s) administered by vein to treat heart failure, to increase the production of urine, increase cardiac performance, and/or reduce cardiac preload or afterload.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Intravenous Diuretic, Inotropic or Vasodilator Augmentation for Heart Failure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE" nciodm:ExtCodeID="C119209">
                    <nciodm:CDISCDefinition>Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure) greater than or equal to 18 mmHg, central venous pressure greater than or equal to 12 mmHg, or a cardiac index less than 2.2 L/min/m2. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Heart Failure by Invasive Diagnostic Technique</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="ISCHEMIC STROKE" nciodm:ExtCodeID="C95802">
                    <nciodm:CDISCDefinition>Ischemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Ischemic Cerebrovascular Accident</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="LOSS OF A SIDE BRANCH" nciodm:ExtCodeID="C119210">
                    <nciodm:CDISCDefinition>Angiographic loss of patency of a side branch.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Loss of Patency of Side Branch</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="LOSS OF MAJOR CORONARY" nciodm:ExtCodeID="C119211">
                    <nciodm:CDISCDefinition>Angiographic loss of patency of a major epicardial vessel.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Loss of Patency of Major Vessel</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="MECHANICAL OR SURGICAL INTERVENTION" nciodm:ExtCodeID="C119212">
                    <nciodm:CDISCDefinition>Mechanical circulatory support (e.g., intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artificial heart) or mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis). (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Vasculature Mechanical or Surgical Intervention</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="NEW LOSS OF VIABLE MYOCARDIUM" nciodm:ExtCodeID="C119213">
                    <nciodm:CDISCDefinition>Non-invasive imaging evidence of a loss of viable myocardium when compared with the most recent previous non-invasive imaging study.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>New Loss of Viable Myocardium by Non-invasive Imaging Technique</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="NEW REGIONAL WALL MOTION ABNORMALITY" nciodm:ExtCodeID="C119214">
                    <nciodm:CDISCDefinition>Non-invasive imaging evidence of a decrease in regional wall motion contractility compared with the most recent previous non-invasive imaging study.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>New Regional Wall Motion Abnormality by Non-invasive Imaging Technique</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="NON-INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE" nciodm:ExtCodeID="C119215">
                    <nciodm:CDISCDefinition>Non-invasive diagnostic evidence of clinically significant elevated left- or right-sided ventricular filling pressure or low cardiac output. For example, echocardiographic criteria could include: E/e' greater than 15 or D-dominant pulmonary venous inflow pattern, plethoric inferior vena cava with minimal collapse on inspiration, or decreased left ventricular outflow tract (LVOT) minute stroke distance (time velocity integral (TVI)). (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Heart Failure by Non-invasive Diagnostic Technique</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="PERIPHERAL EDEMA" nciodm:ExtCodeID="C78262">
                    <nciodm:CDISCDefinition>Increased tissue fluid indicated by perceptible pitting indentation on lower leg, foot or sacrum after palpation.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Edema Limbs</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="PULMONARY RALES/CRACKLES/CREPITATIONS" nciodm:ExtCodeID="C119216">
                    <nciodm:CDISCDefinition>Abnormal breath sounds caused by the accumulation of fluid in the lungs.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Rales</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="RADIOLOGICAL EVIDENCE OF PULMONARY CONGESTION" nciodm:ExtCodeID="C119217">
                    <nciodm:CDISCDefinition>Imaging findings consistent with increased intravascular blood volume in the lungs.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Pulmonary Congestion by Radiological Technique</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="RESTING ECG CHANGES" nciodm:ExtCodeID="C119218">
                    <nciodm:CDISCDefinition>New or worsening ST or T wave changes on resting ECG (in the absence of confounders, such as LBBB or LVH), defined as either: a) Transient ST elevation (duration less than 20 minutes): new ST elevation at the J point in any two contiguous leads (other than leads V2-V3) of greater than or equal to 0.1 mV. In leads V2-V3, the following cut-points apply: greater than or equal to 0.2 mV in men greater than or equal to 40 years, greater than or equal to 0.25 mV in men less than 40 years, and greater than or equal to 0.15 mV in women, or b) ST depression and T-wave changes: new horizontal or down-sloping ST depression greater than or equal to 0.05 mV in two contiguous leads and/or new T inversion greater than or equal to 0.3 mV in two contiguous leads with prominent R wave or R/S ratio greater than 1.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Resting ECG Changes</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="S3 GALLOP" nciodm:ExtCodeID="C61455">
                    <nciodm:CDISCDefinition>Presence of mid-diastolic heart sound.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>S3 Gallop</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="SLOW-FLOW/NO-FLOW/EMBOLIZATION" nciodm:ExtCodeID="C119219">
                    <nciodm:CDISCDefinition>Angiographic reduction of flow into the coronary microcirculation.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Flow Reduced in Coronary Microcirculation</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="STENT THROMBOSIS ARC ACUTE" nciodm:ExtCodeID="C123439">
                    <nciodm:CDISCDefinition>0 to 24 hours after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Academic Research Council Acute Stent Thrombosis</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="STENT THROMBOSIS ARC LATE" nciodm:ExtCodeID="C123440">
                    <nciodm:CDISCDefinition>Greater than 30 days to 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Academic Research Council Late Stent Thrombosis</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="STENT THROMBOSIS ARC SUBACUTE" nciodm:ExtCodeID="C123441">
                    <nciodm:CDISCDefinition>Greater than 24 hours to 30 days after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Academic Research Council Subacute Stent Thrombosis</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="STENT THROMBOSIS ARC VERY LATE" nciodm:ExtCodeID="C123442">
                    <nciodm:CDISCDefinition>Greater than 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Academic Research Council Very Late Stent Thrombosis</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 1 MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119220">
                    <nciodm:CDISCDefinition>Spontaneous clinical syndrome related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection, with resulting intraluminal thrombus, and leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. This classification requires a) detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value greater than 99th percentile of the upper reference limit (URL) and b) at least one of the following: symptoms of myocardial ischemia; new or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB) on the ECG; development of pathological Q waves on the ECG; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; identification of an intracoronary thrombus by angiography or autopsy. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 1 Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 2 MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119221">
                    <nciodm:CDISCDefinition>Ischemic imbalance: Spontaneous clinical syndrome where a condition other than coronary artery disease contributes to an imbalance between myocardial oxygen supply and/or demand, e.g. coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-arrhythmias, anemia, respiratory failure, hypotension, and hypertension with or without left ventricular hypertrophy. This classification requires detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value greater than 99th percentile of the upper reference limit (URL) and b) at least one of the following: symptoms of myocardial ischemia; new or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB) on the ECG; development of pathological Q waves on the ECG; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 2 Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 3 MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119222">
                    <nciodm:CDISCDefinition>Death, No Biomarkers: Death where symptoms suggestive of myocardial ischemia are present, and with (presumed) new ischemic changes or new LBBB on ECG, but where death occurs before cardiac biomarkers can be obtained, or before cardiac biomarker values could rise. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 3 Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 4A MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119223">
                    <nciodm:CDISCDefinition>PCI Related: PCI Related Myocardial infarction associated with and occurring within 48h of percutaneous coronary intervention, with elevation of cardiac biomarker values to greater than 5x 99th percentile of the upper reference limit (URL) in patients with normal baseline values (less than or equal to 99th percentile URL), or a rise of cardiac biomarker values greater than or equal to 20% if the baseline values are elevated and are stable or falling. This classification also requires at least one of the following: symptoms of myocardial ischemia; new ischemic ECG changes or new LBBB; angiographic loss of patency of a major coronary artery or a side branch or persistent slow- or no-flow or embolization; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 4A Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 4B MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119224">
                    <nciodm:CDISCDefinition>Stent Thrombosis: Myocardial infarction associated with stent thrombosis as detected by coronary angiography or at autopsy, where symptoms suggestive of myocardial ischemia are present, and with a rise and/or fall of cardiac biomarkers values, with at least one value greater than 99th percentile of the upper reference limit. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 4B Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 4C MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119225">
                    <nciodm:CDISCDefinition>Stent Restenosis: Myocardial infarction associated with stent restenosis as detected by coronary angiography or at autopsy, occurring more than 48h after percutaneous coronary intervention, without evidence of stent thrombosis but with symptoms suggestive of myocardial ischemia, and with elevation of cardiac biomarker values to greater than 99th percentile of the upper reference limit (URL). This classification also requires the following: does not meet criteria for any other classification of myocardial infarction; presence of a greater than or equal to 50 percent stenosis at the site of previous successful stent PCI. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 4C Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="TYPE 5 MYOCARDIAL INFARCTION" nciodm:ExtCodeID="C119226">
                    <nciodm:CDISCDefinition>CABG Related: Myocardial infarction associated with and occurring within 48h of coronary artery bypass graft surgery, with elevation of cardiac biomarker values to greater than 10x 99th percentile of the upper reference limit (URL) in patients with normal baseline cardiac biomarker values (less than or equal to 99th percentile URL). This classification also requires at least one of the following: new pathologic Q waves or new LBBB on ECG; angiographic new graft or new native coronary artery occlusion; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Joint Task Force Type 5 Myocardial Infarction</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="UNDETERMINED STROKE" nciodm:ExtCodeID="C3390">
                    <nciodm:CDISCDefinition>An acute episode of focal or global neurological dysfunction caused by presumed brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction but with insufficient information to allow categorization as ischemic or hemorrhagic.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Cerebrovascular Accident</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="URGENT HEART FAILURE VISIT" nciodm:ExtCodeID="C119227">
                    <nciodm:CDISCDefinition>An event where the patient has an urgent, unscheduled office/practice or emergency department visit for a primary diagnosis of heart failure (HF) but is not admitted to the hospital, where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF, with the exception that changes to oral diuretic therapy do no qualify as initiation or intensification of treatment. (Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran, R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions For Cardiovascular Endpoint Events In Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular End Points Data Standards) J Am Coll Cardiol 2014; In Press)</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>ER or Office Visit Due to Heart Failure</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="VOLUME OVERLOAD" nciodm:ExtCodeID="C50591">
                    <nciodm:CDISCDefinition>Excessive accumulation of intravascular fluid resulting from compromised regulatory mechanisms.</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Hypervolemia</nciodm:PreferredTerm>
                </EnumeratedItem>
                <EnumeratedItem CodedValue="WORSENED END-ORGAN PERFUSION" nciodm:ExtCodeID="C119228">
                    <nciodm:CDISCDefinition>Decreased blood supply to the vital organs (kidney, liver, lungs, heart, brain).</nciodm:CDISCDefinition>
                    <nciodm:PreferredTerm>Worsened End-Organ Perfusion</nciodm:PreferredTerm>
                </EnumeratedItem>
                <nciodm:CDISCSubmissionValue>CVFARS</nciodm:CDISCSubmissionValue>
                <nciodm:CDISCSynonym>Cardiovascular Findings About Results</nciodm:CDISCSynonym>
                <nciodm:PreferredTerm>CDISC SDTM Cardiovascular Findings About Results Terminology</nciodm:PreferredTerm>
            </CodeList>
            
